EGFR and neoplasm: Regarding stage II–III nonsquamous NSCLC patients receiving surgery and platinum-based adjuvant chemotherapy, it was found that EGFR alteration was an independent predictor for shorter relapse-free survival (RFS) and tumour recurrence [9].